Modular Medical Inc. has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions, scheduled to take place from June 20-23, 2025, in Chicago, Illinois. The company will present findings from a study investigating the pump delivery of a GLP-1R agonist, specifically exenatide, in comparison to intermittent dosing of semaglutide. The presentation, set for June 22, 2025, will feature a poster titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse." This study examines the effects of pump-delivery of a short-acting GLP-1RA on weight, food intake, and glucose tolerance in diet-induced obese mice. Results from this study will be shared during a General Poster Session at the event.